Anuh Pharma Q4 FY23 earnings call: Revenue & Margins
Q4 FY23 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Anuh Pharma Ltd Q4 FY23 key numbers
- Revenue
- Operating revenue for the quarter ended 31/03/2023 was Rs. 157.31 Cr, up from Rs. 138.73 Cr in the same quarter of the previous year, showing a year-on-year increase of approximately 13.5%.
As stated in Anuh Pharma Ltd's Q4 FY23 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Anuh Pharma Ltd's Q4 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Operating revenue for the quarter ended 31/03/2023 was Rs. 157.31 Cr, up from Rs. 138.73 Cr in the same quarter of the previous year, showing a year-on-year increase of approximately 13.5%. Quarterly EBITDA: Rs. 15.27 Cr (up 5% QoQ compared to Rs. 14.54 Cr).
From Anuh Pharma Ltd's Q4 FY23 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Operating revenue for the quarter ended 31/03/2023 was Rs. 157.31 Cr, up from Rs. 138.73 Cr in the same quarter of the previous year, showing a year-on-year increase of approximately 13.5%.
- For the full FY 2023, operating revenue was Rs. 527.49 Cr compared to Rs. 486.65 Cr in FY 2022, an 8% year-on-year growth.
- Export sales increased by about 26.92% from Rs. 228 Cr in FY 2022 to Rs. 289 Cr in FY 2023.
2 more points from Anuh Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned Capex of Rs 5 Cr for capacity enhancement to support a target growth rate of 20% (Page 7).
- Manufacturing capacity at L&L site for corticosteroids enhanced to 12 MTPA (Page 30).
- Focus on capacity improvements and efficiency.
- R&D facility: Dedicated 10,000 sq. ft. in-house lab with 16 scientists operational for new product/process development (Page 28).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Anuh Pharma Ltd's call on order book
Create a free account to keep reading this call
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anuh Pharma Ltd Q4 FY23 results?
Operating revenue for the quarter ended 31/03/2023 was Rs. 157.31 Cr, up from Rs. 138.73 Cr in the same quarter of the previous year, showing a year-on-year increase of approximately 13.5%. Quarterly EBITDA: Rs. 15.27 Cr (up 5% QoQ compared to Rs. 14.54 Cr).
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
Planned Capex of Rs 5 Cr for capacity enhancement to support a target growth rate of 20% (Page 7).
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
